REGN
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc historical holders
total: 8
Parnassus Endeavor Fund Regeneron Pharmaceuticals Inc transactions over time
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 1
- Reduced:
- 3
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
Parnassus Endeavor Fund has been an institutional investor in Regeneron Pharmaceuticals Inc (REGN) since 2025 Q2. According to 2026 Q2 report, Parnassus Endeavor Fund holds 95,378 shares with a market value of roughly $59.47M representing 1.12% of their equity portfolio. The fund/company first acquired REGN in 2025 Q2, initially purchasing 101,084 shares. Since the initial investment, Parnassus Endeavor Fund has made 4 more transactions in this position.
Does Parnassus Endeavor Fund still hold REGN?
Yes, Parnassus Endeavor Fund continues to hold Regeneron Pharmaceuticals Inc (REGN). According to their 2026 Q2 report, they maintain a position of 95,378 shares valued at approximately $59.47M, representing 1.12% of their equity portfolio.
When did Parnassus Endeavor Fund first invest in REGN?
Parnassus Endeavor Fund first invested in Regeneron Pharmaceuticals Inc (REGN) in 2025 Q2 at the reported quarter-end price of $525.00 per share, acquiring 101,084 shares in their initial purchase.
What is Parnassus Endeavor Fund's average cost basis for REGN?
Based on historical transaction data, Parnassus Endeavor Fund's estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) is approximately $527.31 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $527.31
- Weighted AVG sell price:
- $722.77
REGN transactions history by Parnassus Endeavor Fund
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.12%
|
95,378
|
$623.54
|
$59,471,998
|
-2.17% (-2,117)
|
-0.03%
|
|
2026 Q1
|
1.63%
|
97,495
|
$772.64
|
$75,328,537
|
+0.98% (+950)
|
+0.02%
|
|
2025 Q4
|
1.56%
|
96,545
|
$771.87
|
$74,520,189
|
-4.43% (-4,478)
|
-0.07%
|
|
2025 Q3
|
1.21%
|
101,023
|
$562.27
|
$56,802,202
|
-0.06% (-61)
|
-0%
|
|
2025 Q2
|
1.17%
|
101,084
|
$525.00
|
$53,069,100
|
new
|
+1.17%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.